|

Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC

RECRUITINGN/ASponsored by Chinese University of Hong Kong
Actively Recruiting
PhaseN/A
SponsorChinese University of Hong Kong
Started2026-10-19
Est. completion2029-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

This is a prospective, multi-centre randomised trial comparing between cTURBT plus 1-year BCG therapy, and ERBT plus 1-year BCG therapy, in patients with intermediate-risk or high-risk NMIBC.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age 18 years or above
* Fulfil any one of the following three criteria:

  1. Recurrent bladder tumour
  2. Multiple bladder tumours
  3. Any bladder tumour size of \>1cm

Exclusion Criteria:

* EAU low-risk NIMBC as intravesical BCG therapy should not be offered (5)
* EAU very high-risk NMIBC as upfront radical cystectomy should be offered (5)
* Any prior use of intravesical BCG therapy
* Presence or prior history of upper urinary tract malignancy
* Presence of clinically significant cardiovascular disease (History of acute myocardial infarction, presence of uncontrolled angina within 3 months before screening, New York Heart Association Class III or IV congestive heart failure, presence of ventricular arrhythmias, or presence of second-degree or third-degree heart block) (16)
* Presence of GOLD Stage III or IV chronic obstructive pulmonary disease
* ECOG performance status ≥ 2 (Ambulatory and capable of all self-care but unable to carry our any work activities) (18)
* History of bleeding disorder or use of anti-coagulants
* Pregnancy
* Presence of other active malignancy

Conditions2

Bladder CancerCancer

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.